Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news claude_news gdelt_news congress_bills wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a long-dated (Jan 2029) Kalshi political-action market whose resolution hinges on whether a Trump administration action actually zeroes out the cost of at least one IVF cycle — a much higher bar than the Feb 2025 IVF executive order or the Oct 2025 fertility-drug pricing deal. Primary anchor is the Kalshi price itself; then I need the factual state of administration IVF policy, any pending rules/legislation, and cross-venue prices.

# Current state Kalshi prices this market at 13% YES. As of mid/late-2026, no federal action has eliminated the cost of even one IVF cycle — only voluntary drug discounts (EMD Serono/TrumpRx, ~$2,200/cycle savings) and a proposed (not final) DOL/HHS/Treasury "excepted fertility benefit" rule with a $120,000 lifetime cap, which employers are not required to offer. The Feb 2025 executive order only directed policy recommendations, missed its own 90-day deadline, and created no mandate. # Timeline of key events - 2025-02-18 — Trump signs EO 14216, directing Domestic Policy Council to submit IVF cost-reduction recommendations within 90 days; no coverage mandate (confirmed, whitehouse.gov). - 2025-05-19 — 90-day deadline passes with no public recommendations released (confirmed, reproductivefreedom.house.gov). - 2025-06 to 2025-11 — Multiple Democratic bills introduced (Protect IVF Act, Access to Fertility Treatment Act, Equal Access to Reproductive Care Act, Veteran Families Health Services Act) — all referred to committee, no floor votes (confirmed, congress.gov). - 2025-10-16 — White House/EMD Serono deal announced: up to 84% discount on 3 IVF drugs via TrumpRx (launch ~early 2026); DOL/HHS/Treasury issue guidance permitting "excepted benefit" fertility plans for employers (voluntary) (confirmed, CNN/USNews/Al Jazeera). - 2026 (Jan–Feb) — TrumpRx platform launches (reported, slight date discrepancies across sources). - 2026-05-11/13 — Trump publicly touts "fertility/maternal healthcare" push; gaffe-heavy press events; new "mom website" launched (reported, Newsweek/Atlanta Black Star). - 2026-05-13 — DOL/HHS/Treasury propose "Excepted Fertility Benefits" rule: standalone employer fertility insurance, $120k lifetime cap, still optional for employers (confirmed, Federal Register). - 2026-05-21 — CNN reports IVF costs still "a long way off" from dropping as promised (confirmed). - 2026-06-10 — Trump admin moves to protect frozen embryos from destruction (reported, Daily Signal) — unrelated to cost/coverage. - 2026-06-24/07-23 — More Democratic bills (Let Doctors Provide Reproductive Health Care Act; Right to IVF Act of 2026) introduced, referred to committee (confirmed, congress.gov). - 2026-07-21 — Catholic bishops ask Trump to change the IVF insurance rule (theological objection to embryo destruction incentives); Senator criticizes GOP for blocking military IVF coverage despite Trump's "free IVF" pledge (reported). # Event Will Trump's administration eliminate the full cost of at least one IVF cycle (via any presidential action) before Jan 20, 2029? # Outcomes to forecast Yes / No # Kalshi market anchor **13% YES** (current). 30-day change: -1%; 7-day: flat. Price range over 62 days of data: 13–17%, trending down slightly. Average daily volume only 26 contracts — thin liquidity, wide potential for mispricing but also low information content in the price. # Sub-question answers 1. **Kalshi price/history/liquidity** — 13% YES currently, down from a high of 17%; ~26 contracts/day average volume, 62 days of data — thin but stable market (kalshi_direct). 2. **Concrete actions taken** — EO 14216 (Feb 2025, recommendations only); EMD Serono/TrumpRx drug discount deal (Oct 2025, saves ~$2,200/cycle on drugs, not full cost); DOL/HHS/Treasury guidance/proposed rule on voluntary "excepted" employer fertility benefits ($120k lifetime cap, proposed May 2026, not finalized, not mandatory). None eliminate the full cost of a cycle (claude_news x2, KFF, ASRM). 3. **Pending rules/mandates with plausible pre-2029 effective date** — The excepted-benefit rule remains proposed, voluntary, and capped — not a full-cost-elimination mechanism even if finalized. No ACA essential-benefit mandate, Medicaid/Medicare IVF mandate, or FEHB overhaul is underway; FEHB governed separately by OPM, unaffected by DOL rule (fedtools.com). 4. **Federal legislation prospects** — Right to IVF Act of 2026 (S.5108, Duckworth), Protect IVF Act, Access to Fertility Treatment Act, etc. — all Democrat-sponsored, referred to committee, no votes scheduled; divided/GOP-controlled Congress has repeatedly blocked such bills (Murray, Duckworth quoted; congress_bills). 5. **Base rate for full implementation of costly, unappropriated campaign promise** — Code-execution modeling estimates historical base rate for big-mandate campaign promises fully implemented within a term at ~10–20%; discounted for IVF-specific frictions (60-vote Senate requirement, GOP mandate aversion, no appropriation) to ~8–12% remaining probability. 6. **Cross-market signals** — No matching Polymarket market found (0 matches). Kalshi's own "Trump manufacturing" (18%) and "Trump govt cuts $250B+" (4.1%) markets suggest similar skepticism toward large unfunded Trump promises being fully realized. # Key facts (high-confidence, factual) 1. [whitehouse.gov] EO 14216 (Feb 2025) directed recommendations only, no mandate. 2. [reproductivefreedom.house.gov] 90-day deadline missed; no recommendations released as of May 2025. 3. [CNN/USNews] Oct 2025 EMD Serono deal cuts drug costs ~70-84%, saving up to $2,200/cycle — partial, not full elimination. 4. [Federal Register, PBS] May 2026 proposed rule creates voluntary "excepted" fertility benefit category, $120k lifetime cap, not mandatory. 5. [ASRM, KFF] Federal actions do not preempt state mandates nor create insurer/employer requirement; multiple outlets (PBS, KFF, CNN) explicitly state actions fall short of "free IVF." 6. [congress.gov] All IVF coverage-expansion bills in 119th Congress are Democrat-sponsored and stalled in committee. # Cross-market signals - Kalshi related: "Trump manufacturing" 18%, "Trump govt spending cuts $250B+" 4.1% — comparable skepticism toward ambitious unfunded Trump pledges. - Polymarket: No matching market found. - Sportsbook implied: N/A (not applicable to policy market). # Analyst opinions and speculation - KFF, ASRM, PBS, CNN analysts consistently describe actions as "falling short" of the free-IVF promise. - Sen. Warren, Duckworth, Murray (Democrats) call efforts "PR stunt" / "broken promise." - Catholic bishops object to insurance-rule specifics (embryo-related), an unrelated friction that could complicate/delay any rule finalization. - Newsweek notes "good news/bad news" for Trump's IVF plans re: birth-rate study (mixed political messaging, no policy substance). # Directional lean per outcome - **Yes**: Administration has shown sustained rhetorical commitment (EO, TrumpRx, proposed rule) and ~2.4 years remain; a future reconciliation bill, VA-specific full coverage, or a stronger executive action (e.g., mandating Medicaid/Medicare or federal-employee free cycles) could still emerge. - **No** (favored): No mechanism to date has eliminated full cycle cost; only discounts/voluntary caps exist; legislative path blocked by GOP-controlled/divided Congress; explicit expert/media consensus says current trajectory falls well short of "free"; costs ($15-30B+/yr) exceed likely appropriation. # Gaps / unknowns - Whether the May 2026 proposed rule will be finalized, and if any employer actually offers a $0-out-of-pocket plan under it. - Whether military/VA IVF coverage (blocked per Alternet headline) could be revived and made fully free for a covered population, satisfying "at least one cycle" language. - No visibility into any 2027-2028 legislative or reconciliation vehicle. - Kalshi thin volume (26/day) limits confidence that 13% reflects deep information aggregation. # Calibration anchors - Kalshi current YES price: 13% (anchor). - Code-execution base-rate model: calibrated range 6-13%, central estimate ~8-9%. - Precedent: Kalshi "Trump manufacturing" (18%) and "govt cuts $250B" (4.1%) markets show similar deep discounting of large Trump policy pledges lacking clear implementation mechanism.

1. Both forecasters converge almost identically (9% vs 11%) around the model's central estimate without independently stress-testing the "at least one cycle" resolution language — the brief notes this could be satisfied by a narrower carve-out (VA/military/federal-employee), yet neither quantifies how plausible that specific pathway is given the brief explicitly flags "Senator criticizes GOP for blocking military IVF coverage despite Trump's 'free IVF' pledge" — suggesting even that narrow path is currently blocked, which should push probability lower than they land. 2. Neither forecaster explicitly addresses the ambiguity risk in resolution: if a future administrative rule or executive order full-funds even a small pilot/demonstration population (e.g., a single VA facility), resolvers might could count that as "Yes" even if it's not broad policy — this ambiguity could cut either direction and wasn't discussed by either forecast. 3. Both anchor tightly to the Kalshi price (13%) and treat the base-rate model's 6-13% range as the ceiling, but the brief's cross-market comparators ("Trump manufacturing" 18%, "govt cuts $250B+" 4.1%) show a much wider spread of skepticism for unfunded Trump pledges — neither forecaster explains why IVF should sit near the middle of that range rather than closer to the 4-5% extreme, given IVF has arguably weaker implementation mechanism (no appropriation, blocked Congress) than manufacturing pledges. 4. Neither forecast grapples with the Catholic bishops' theological objection as a friction that could delay or kill the rule's finalization — this is a distinct downside risk (beyond generic "GOP mandate aversion") that could push probability even lower but isn't factored in explicitly. 5. Both forecasts treat the thin liquidity (26 contracts/day) as a reason to trust the base-rate model over the market, but neither considers that thin liquidity could equally mean the market is stale/uninformative in the *other* direction — e.g., it may not have priced in the July 2026 bishops' pushback or the "still a long way off" CNN reporting from May 2026, which are more recent bearish signals than the price update reflects. 6. Both forecasts are very close to each other (9% and 11%) and give a similar rationale, showing insufficient independent variation — an outside skeptic might expect more disagreement given the genuine uncertainty flagged in "Gaps/unknowns" (e.g., unknown 2027-2028 legislative vehicles), suggesting both may be anchoring too hard on the same base-rate tool rather than exploring tail scenarios like a reconciliation bill surprise.

8% (medium confidence)

Yes: 8% No: 92%

Nothing enacted to date eliminates the full cost of an IVF cycle: EO 14216 only requested recommendations (deadline missed), the EMD Serono/TrumpRx deal shaves ~$2,200 in drug costs, and the May 2026 'excepted fertility benefit' rule is voluntary, capped at $120k, and still merely proposed — with new theological/bishop friction that could delay finalization. Legislative routes are dead: every coverage-mandate bill is Democrat-sponsored and stalled, a mandate would cost $15-30B+/yr with no appropriation and a 60-vote Senate hurdle, and even the narrow military/VA carve-out that could satisfy 'at least one cycle' has reportedly been blocked by GOP lawmakers — a point the critique correctly notes both forecasters left unquantified. That pushes me slightly below both forecasts and well below the thin, likely stale 13% Kalshi anchor (26 contracts/day, unlikely to have absorbed mid-2026 bearish reporting), toward the base-rate model's central 8-9%. I retain a modest tail for a 2027-28 reconciliation surprise or a small fully-funded federal/VA pilot that a resolver could count, so 8% rather than the 4-5% extreme.

Total pipeline time: 253.0s